Soleno Therapeutics Faces Securities Class Action Amid VYKAT XR Launch Disruptions

Soleno Therapeutics ($SLNO) is confronting significant legal and market headwinds following a sharply contested securities class action lawsuit, triggered by mounting concerns over the safety profile and commercial viability of its flagship hyperphagia treatment VYKAT™ XR. The lawsuit, filed by prominent securities litigation firm Hagens Berman, alleges that company management misrepresented critical safety data and the drug's commercial prospects to investors. The legal action underscores a dramatic reversal of fortune for the biotech company, whose shares have plummeted nearly 40% since an August 2025 short seller report first raised red flags about the drug's real-world safety profile.

The Timeline and Market Collapse

The cascade of problems began in August 2025, when a short seller report raised serious safety concerns regarding VYKAT XR, focusing specifically on fluid retention complications and hospitalizations associated with the drug. The allegations triggered an immediate and substantial market reaction, with Soleno's stock declining 26% on November 5, 2025 alone—a single-day rout that reflected investor panic over the credibility of the company's safety disclosures.

Key developments in the timeline include:

• August 2025: Short seller report published raising safety concerns
• November 5, 2025: Stock collapsed 26% in single trading session
• Post-report period: Cumulative decline of approximately 40% from initial short report
• Current status: Pending securities class action lawsuit from Hagens Berman

The litigation specifically challenges Soleno's representations regarding VYKAT XR's safety profile, arguing that management failed to adequately disclose known risks and complications associated with the treatment. The lawsuit further contends that the company overstated the commercial viability and market opportunity for the drug, misleading institutional and retail investors about near-term revenue generation potential.

Market Context and Industry Implications

VYKAT XR was positioned as Soleno's cornerstone therapeutic asset targeting patients with hyperphagia, a rare eating disorder characterized by excessive hunger and food consumption. The drug represented a critical growth driver for the biotech company and had generated considerable investor enthusiasm upon entering the commercial market. However, the emergence of safety concerns has dramatically undermined confidence in both the asset itself and management's credibility.

The situation reflects broader vulnerabilities within the biotechnology sector, particularly among smaller, pre-profitability companies dependent on single or limited pipeline assets. The rapid deterioration of Soleno's market position demonstrates how quickly investor confidence can evaporate when safety questions surface post-launch, especially in rare disease markets where patient populations are limited and individual adverse events carry outsized reputational weight.

The hyperphagia treatment space remains relatively nascent, with limited competitive alternatives. The controversy surrounding VYKAT XR raises questions about regulatory oversight at the FDA level and whether pre-launch safety data adequately predicted real-world complications. This dynamic could have implications for other rare disease therapies in development and the standards applied during clinical trials versus post-market monitoring.

Investor Implications and Forward Outlook

For equity investors in Soleno Therapeutics ($SLNO), the securities class action represents both immediate and longer-term risks. The lawsuit could trigger substantial legal expenses and potential settlements or judgments, directly impacting the company's financial position. More critically, the allegations undermine the credibility necessary for management to restore investor confidence, potentially complicating future capital raises or partnerships.

The broader implications for biotech investors include:

• Heightened due diligence scrutiny: Investors may demand more rigorous independent safety reviews before backing pre-commercial biotech assets
• Discount to rare disease stocks: Market may apply greater discounting to single-asset biotech companies with limited diversification
• Regulatory recalibration: Potential for enhanced FDA post-market surveillance requirements for rare disease therapies
• Litigation risk premium: Insurance and litigation costs may rise for biotech firms with controversial launches

The 40% stock decline represents a severe loss of shareholder value and reflects market skepticism about management's ability to navigate the crisis. If the short seller report's safety allegations are substantiated, Soleno may face additional regulatory consequences, including potential label restrictions or market withdrawals. Conversely, if the company successfully defends against these allegations through clinical or real-world data, stock recovery could be substantial, though investor trust would require rebuilding.

The litigation process itself will likely prove lengthy, potentially extending 2-3 years or more. During this period, Soleno's ability to execute on any remaining pipeline programs or generate new revenues from VYKAT XR will be severely constrained by legal uncertainty and reputation damage.

Conclusion

The combination of safety concerns, market collapse, and securities litigation represents an existential challenge for Soleno Therapeutics. The company now faces a dual battle: defending against legal allegations while attempting to demonstrate that VYKAT XR can be safely and effectively deployed in the market. The outcome will likely determine not only the company's financial viability but also set precedent for how the biotech industry manages post-launch complications in rare disease therapeutics. For investors, the situation serves as a cautionary reminder about concentration risk in pre-profitability biotech companies and the speed with which market sentiment can reverse when safety questions emerge.